Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Liquid Biopsies Remain Wait and See for Some Clinicians
Circulating Biomarker Assays Promise to Refresh Cancer Profiling and Monitoring Practices
For full access to this article login to GEN Select now.
Enzymatics Enriches NGS with AMP
Targeted Sequencing Technology Enhances Gene Mutation Identification and Discovery
- In transforming itself from a reagents supplier to a next-generation sequencing (NGS) applications company, Enzymatics is advancing the genomics industry. While Enzymatics continues to support and expand its fast-growing core business—reagents and kits for original equipment manufacturers—it is also taking advantage of a new technology—Anchored Multiplex PCR (AMP™) chemistry. ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.